Purinergic Receptors and their Modulators (eBook)

This book overviews purinergic receptors that are playing key roles in human and pathophysiological processes. The book elaborates on how selective P1 and P2 modulators have been developed as therapeutics for a variety of diseases. It also provides an overview of current perspectives in the design of purinergic receptor modulators and future challenges such as the availability of selective ligands for all receptor subtypes.

This book is a valuable resource for scholars working in the field of medicinal chemistry, as well as researchers in the industry, providing readers with a comprehensive understanding of adenosine receptor biology and its therapeutic potential.

Claudiu T. Supuran is a Full Professor of Medicinal Chemistry at Dipartimento Neurofarba, Universita` degli Studi di Firenze, Sezione di Scienze Farmaceutiche e Nutraceutiche, Florence, Italy. He received his BSc in Chemistry from the Polytechnic University of Bucharest, Romania (1987), and Ph. D. in Chemistry at the same university in 1991. His research interests focus on drug development against Carbonic anhydrases and other enzymes. He has published 2000+ research articles on  enzyme inhibitors/activators, being one of the most cited medicinal chemists worldwide. His research is also focused on metalloenzymes cloning, characterization and inhiibtion studies, carbonic anhydrases, proteases, heterocyclic chemistry, chemistry of sulfonamides, sulfamates and sulfamides, X-ray crystallography of metallo-enzymes, biologically active organo-element derivatives, quantitative structure-activity relationship (QSAR) studies, metal-based drugs, cyclooxygenases inhibitors, serine proteases, matrix metalloproteinases, bacterial proteases, antivirals, antitumor drugs, ophthalmologic drugs and amino acid derivatives. One sulfonamide carbonic anhydrase inhibitor discovered in his laboratory, SLC-0111, completed Phase I clinical trials as antitumor/antimetastatic agent in 2014 and is presently in Phase Ib/II clinical trials in North America, being developed for the treatment of advanced, metastatic solid tumors.